See All Slides - tctmd.com

Slides

Presentation TCT 2013

Regulatory Consultant

Presenter: Semih Oktay

October 30, 2013

Presentation TCT 2013

Real-Time Device Surveillance

Presenter: Mladen Vidovich

October 30, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

Presentation TCT 2013

Does Revascularization Benefit Patients with Systolic Dysfunction (With or Without Ischemia and/or Viability)

Presenter: Robert Bonow

October 29, 2013

Presentation TCT 2013

The Imaging Revolution Will Forever Change the Approach to Coronary Artery Disease

Presenter: Stephan Achenbach

October 29, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

Case Presentation and Topic Review: Does This HCM Patient Need an ICD?

Presenter: Alexander Osiev

October 29, 2013

Presentation TCT 2013

TCT-38. Three-year clinical data of the BIOSOLVE-I Study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis

Presenter: Michael Haude

October 29, 2013

Presentation TCT 2013

Complication Following Left Atrial Appendage Occlusion

Presenter: Brian Whisenant

October 29, 2013

Presentation TCT 2013

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

Presenter: Masato Nakamura

October 29, 2013

Advertisement

Slides

Regulatory Consultant

Real-Time Device Surveillance

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Does Revascularization Benefit Patients with Systolic Dysfunction (With or Without Ischemia and/or Viability)

The Imaging Revolution Will Forever Change the Approach to Coronary Artery Disease

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Case Presentation and Topic Review: Does This HCM Patient Need an ICD?

TCT-38. Three-year clinical data of the BIOSOLVE-I Study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis

Complication Following Left Atrial Appendage Occlusion

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content